IATRA Life Sciences

Iatra Life Sciences is a San Francisco-based biotechnology company focused on developing next-generation small molecule therapeutics for difficult-to-drug targets in oncology. The company was co-founded by Dr. Kevan Shokat, whose pioneering work led to the first covalent inhibitors of KRAS G12C. Iatra leverages advanced covalent chemistry and structural biology to target the RAS GTPase family and other oncogenic drivers. By addressing resistance mechanisms and expanding the range of targetable mutations, the company aims to provide new treatment options for patients with solid tumors. Iatra is currently in the pre-clinical stage and is backed by leading life science investors like The Column Group.